Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer

Review (11 RCTs; n=5088) reported equivalent overall survival, one‐year survival, and response rate in pts treated with carboplatin or cisplatin doublet with third‐generation chemotherapy drugs with carboplatin causing more thrombocytopenia, and cisplatin more nausea/vomiting.

Cochrane Database of Systematic Reviews